Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial
Jörge E. Cortes(Augusta University Health), Mark J. Levis(Sidney Kimmel Cancer Center), Neil P. Shah(University of California, San Francisco), Björn Steffen(Goethe University Frankfurt), Jessica K. Altman(Northwestern University), Stephen A. Strickland(Vanderbilt University), Claudia D. Baldus(University Hospital Schleswig-Holstein), Nigel H. Russell(Guy's and St Thomas' NHS Foundation Trust), Norbert Ifrah(Institut National du Cancer), Alexander E. Perl(University of Pennsylvania), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Denise Trone(Unknown), Philippe Rousselot(Université Paris-Saclay), Elihu H. Estey(University of Washington), Deborah Lazzaretto(Daiichi Sankyo (United States)), Giovanni Martinelli(University of Bologna), Hartmut Döhner(University Hospital Ulm), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Catherine C. Smith(University of California, San Francisco), Guy Gammon(Unknown), Tibor Kovacsovics(Hôpital Edouard Herriot), Hervé Dombret(University of London Institute in Paris), Alwin Krämer(Heidelberg University), Alan K. Burnett(Cardiff University)
Cited by 268
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k